APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preclinical Pharmacokinetics Services

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Preclinical Pharmacokinetics Services Market Analysis and Forecast 2026-2032

6 March 2026209 pages

Choose your research edition.

Industry ResearchPreclinical Pharmacokinetics Services Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Preclinical Pharmacokinetics Services Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Preclinical Pharmacokinetics Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preclinical Pharmacokinetics Services Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Preclinical Pharmacokinetics Services Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Preclinical Pharmacokinetics Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Preclinical Pharmacokinetics Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Preclinical Pharmacokinetics Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Preclinical Pharmacokinetics Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Preclinical Pharmacokinetics Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Preclinical Pharmacokinetics Services include Porsolt, Altasciences, Biocytogen, Charles River Laboratories, WuXi AppTec, PyschoGenics, Evotec (Cyprotex), QPS and Aurigene Pharmaceutical Services, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Preclinical Pharmacokinetics Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Preclinical Pharmacokinetics Services, also provides the revenue of main regions and countries. Of the upcoming market potential for Preclinical Pharmacokinetics Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Preclinical Pharmacokinetics Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Preclinical Pharmacokinetics Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Preclinical Pharmacokinetics Services revenue, projected growth trends, production technology, application and end-user industry.

Preclinical Pharmacokinetics Services Segment by Company

Porsolt

Altasciences

Biocytogen

Charles River Laboratories

WuXi AppTec

PyschoGenics

Evotec (Cyprotex)

QPS

Aurigene Pharmaceutical Services

Frontage Laboratories

Dalriada

Sygnature Discovery

Admescope

Imavita

IQVIA Laboratories

Pharmaron

Preclinical Pharmacokinetics Services Segment by Type

LC-MS/MS-Based Preclinical Pharmacokinetics Service

Immunoassay-Based Preclinical Pharmacokinetics Service

Others

Preclinical Pharmacokinetics Services Segment by Application

Innovative Small Molecule Drugs

Biopharmaceuticals

Traditional Chinese Medicine & Natural Products

Others

Preclinical Pharmacokinetics Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Pharmacokinetics Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preclinical Pharmacokinetics Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Pharmacokinetics Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Preclinical Pharmacokinetics Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Preclinical Pharmacokinetics Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Preclinical Pharmacokinetics Services revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Preclinical Pharmacokinetics Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. LC-MS/MS-Based Preclinical Pharmacokinetics Service Major Player Table 3. Immunoassay-Based Preclinical Pharmacokinetics Service Major Player Table 4. Others Major Player Table 5. Global Preclinical Pharmacokinetics Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Innovative Small Molecule Drugs Major Player Table 7. Biopharmaceuticals Major Player Table 8. Traditional Chinese Medicine & Natural Products Major Player Table 9. Others Major Player Table 10. Preclinical Pharmacokinetics Services Industry Trends Table 11. Preclinical Pharmacokinetics Services Industry Drivers Table 12. Preclinical Pharmacokinetics Services Industry Opportunities and Challenges Table 13. Preclinical Pharmacokinetics Services Industry Restraints Table 14. Global Preclinical Pharmacokinetics Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Preclinical Pharmacokinetics Services Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Preclinical Pharmacokinetics Services Market Share by Region (2021-2026) Table 17. Global Preclinical Pharmacokinetics Services Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Preclinical Pharmacokinetics Services Market Share by Region (2027-2032) Table 19. Global Preclinical Pharmacokinetics Services Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Preclinical Pharmacokinetics Services Revenue Market Share by Players (2021-2026) Table 21. Global Preclinical Pharmacokinetics Services Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Preclinical Pharmacokinetics Services Key Players Headquarters & Area Served Table 23. Global Preclinical Pharmacokinetics Services Players, Product Type & Application Table 24. Global Preclinical Pharmacokinetics Services Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Preclinical Pharmacokinetics Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Preclinical Pharmacokinetics Services Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Preclinical Pharmacokinetics Services Revenue Market Share by Type (2021-2026) Table 31. Global Preclinical Pharmacokinetics Services Revenue Market Share by Type (2027-2032) Table 32. Global Preclinical Pharmacokinetics Services Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Preclinical Pharmacokinetics Services Revenue Market Share by Application (2021-2026) Table 36. Global Preclinical Pharmacokinetics Services Revenue Market Share by Application (2027-2032) Table 37. Porsolt Company Information Table 38. Porsolt Business Overview Table 39. Porsolt Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Porsolt Preclinical Pharmacokinetics Services Product Portfolio Table 41. Porsolt Recent Development Table 42. Altasciences Company Information Table 43. Altasciences Business Overview Table 44. Altasciences Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Altasciences Preclinical Pharmacokinetics Services Product Portfolio Table 46. Altasciences Recent Development Table 47. Biocytogen Company Information Table 48. Biocytogen Business Overview Table 49. Biocytogen Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Biocytogen Preclinical Pharmacokinetics Services Product Portfolio Table 51. Biocytogen Recent Development Table 52. Charles River Laboratories Company Information Table 53. Charles River Laboratories Business Overview Table 54. Charles River Laboratories Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Charles River Laboratories Preclinical Pharmacokinetics Services Product Portfolio Table 56. Charles River Laboratories Recent Development Table 57. WuXi AppTec Company Information Table 58. WuXi AppTec Business Overview Table 59. WuXi AppTec Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. WuXi AppTec Preclinical Pharmacokinetics Services Product Portfolio Table 61. WuXi AppTec Recent Development Table 62. PyschoGenics Company Information Table 63. PyschoGenics Business Overview Table 64. PyschoGenics Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. PyschoGenics Preclinical Pharmacokinetics Services Product Portfolio Table 66. PyschoGenics Recent Development Table 67. Evotec (Cyprotex) Company Information Table 68. Evotec (Cyprotex) Business Overview Table 69. Evotec (Cyprotex) Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Evotec (Cyprotex) Preclinical Pharmacokinetics Services Product Portfolio Table 71. Evotec (Cyprotex) Recent Development Table 72. QPS Company Information Table 73. QPS Business Overview Table 74. QPS Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. QPS Preclinical Pharmacokinetics Services Product Portfolio Table 76. QPS Recent Development Table 77. Aurigene Pharmaceutical Services Company Information Table 78. Aurigene Pharmaceutical Services Business Overview Table 79. Aurigene Pharmaceutical Services Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Aurigene Pharmaceutical Services Preclinical Pharmacokinetics Services Product Portfolio Table 81. Aurigene Pharmaceutical Services Recent Development Table 82. Frontage Laboratories Company Information Table 83. Frontage Laboratories Business Overview Table 84. Frontage Laboratories Preclinical Pharmacokinetics Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Frontage Laboratories Preclinical Pharmacokinetics Services Product Portfolio Table 86. Frontage Laboratories Recent Development Table 87. Dalriada Company Information Table 88. Dalriada Business Overview Table 89. Dalriada Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Dalriada Preclinical Pharmacokinetics Services Product Portfolio Table 91. Dalriada Recent Development Table 92. Sygnature Discovery Company Information Table 93. Sygnature Discovery Business Overview Table 94. Sygnature Discovery Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Sygnature Discovery Preclinical Pharmacokinetics Services Product Portfolio Table 96. Sygnature Discovery Recent Development Table 97. Admescope Company Information Table 98. Admescope Business Overview Table 99. Admescope Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Admescope Preclinical Pharmacokinetics Services Product Portfolio Table 101. Admescope Recent Development Table 102. Imavita Company Information Table 103. Imavita Business Overview Table 104. Imavita Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Imavita Preclinical Pharmacokinetics Services Product Portfolio Table 106. Imavita Recent Development Table 107. IQVIA Laboratories Company Information Table 108. IQVIA Laboratories Business Overview Table 109. IQVIA Laboratories Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. IQVIA Laboratories Preclinical Pharmacokinetics Services Product Portfolio Table 111. IQVIA Laboratories Recent Development Table 112. Pharmaron Company Information Table 113. Pharmaron Business Overview Table 114. Pharmaron Preclinical Pharmacokinetics Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Pharmaron Preclinical Pharmacokinetics Services Product Portfolio Table 116. Pharmaron Recent Development Table 117. North America Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Preclinical Pharmacokinetics Services Revenue by Country (2021-2026) & (US$ Million) Table 123. North America Preclinical Pharmacokinetics Services Revenue by Country (US$ Million) & (2027-2032) Table 124. Europe Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Europe Preclinical Pharmacokinetics Services Revenue by Country (2021-2026) & (US$ Million) Table 130. Europe Preclinical Pharmacokinetics Services Revenue by Country (US$ Million) & (2027-2032) Table 131. China Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 132. China Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 133. China Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 134. China Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 136. Asia Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 137. Asia Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 138. Asia Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Preclinical Pharmacokinetics Services Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Asia Preclinical Pharmacokinetics Services Revenue by Region (US$ Million) & (2021-2026) Table 141. Asia Preclinical Pharmacokinetics Services Revenue by Region (US$ Million) & (2027-2032) Table 142. SAMEA Preclinical Pharmacokinetics Services Revenue by Type (2021-2026) & (US$ Million) Table 143. SAMEA Preclinical Pharmacokinetics Services Revenue by Type (2027-2032) & (US$ Million) Table 144. SAMEA Preclinical Pharmacokinetics Services Revenue by Application (2021-2026) & (US$ Million) Table 145. SAMEA Preclinical Pharmacokinetics Services Revenue by Application (2027-2032) & (US$ Million) Table 146. SAMEA Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. SAMEA Preclinical Pharmacokinetics Services Revenue by Country (2021-2026) & (US$ Million) Table 148. SAMEA Preclinical Pharmacokinetics Services Revenue by Country (US$ Million) & (2027-2032) Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Preclinical Pharmacokinetics Services Image Figure 2. Global Preclinical Pharmacokinetics Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preclinical Pharmacokinetics Services Market Size Share 2021 VS 2025 VS 2032 Figure 4. LC-MS/MS-Based Preclinical Pharmacokinetics Service Image Figure 5. Immunoassay-Based Preclinical Pharmacokinetics Service Image Figure 6. Others Image Figure 7. Global Preclinical Pharmacokinetics Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Preclinical Pharmacokinetics Services Market Size Share 2021 VS 2025 VS 2032 Figure 9. Innovative Small Molecule Drugs Image Figure 10. Biopharmaceuticals Image Figure 11. Traditional Chinese Medicine & Natural Products Image Figure 12. Others Image Figure 13. Global Preclinical Pharmacokinetics Services Market Size (US$ Million) & (2021-2032) Figure 14. Global Preclinical Pharmacokinetics Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Preclinical Pharmacokinetics Services Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Preclinical Pharmacokinetics Services Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Preclinical Pharmacokinetics Services Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Preclinical Pharmacokinetics Services Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Preclinical Pharmacokinetics Services Revenue Market Share by Type (2021-2032) Figure 21. Global Preclinical Pharmacokinetics Services Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Preclinical Pharmacokinetics Services Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Preclinical Pharmacokinetics Services Revenue Market Share by Application (2021-2032) Figure 24. North America Preclinical Pharmacokinetics Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032) Figure 26. North America Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032) Figure 27. North America Preclinical Pharmacokinetics Services Revenue Share by Country (2021-2032) Figure 28. United States Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Preclinical Pharmacokinetics Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032) Figure 33. Europe Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032) Figure 34. Europe Preclinical Pharmacokinetics Services Revenue Share by Country (2021-2032) Figure 35. Germany Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Preclinical Pharmacokinetics Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032) Figure 45. China Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032) Figure 46. Asia Preclinical Pharmacokinetics Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032) Figure 48. Asia Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032) Figure 49. Asia Preclinical Pharmacokinetics Services Revenue Share by Region (2021-2032) Figure 50. Japan Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Preclinical Pharmacokinetics Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032) Figure 58. SAMEA Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032) Figure 59. SAMEA Preclinical Pharmacokinetics Services Revenue Share by Country (2021-2032) Figure 60. Brazil Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Preclinical Pharmacokinetics Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • LC-MS/MS-Based Preclinical Pharmacokinetics Service
  • Immunoassay-Based Preclinical Pharmacokinetics Service
  • Others
Applications
  • Innovative Small Molecule Drugs
  • Biopharmaceuticals
  • Traditional Chinese Medicine & Natural Products
  • Others
Companies covered
  • Porsolt
  • Altasciences
  • Biocytogen
  • Charles River Laboratories
  • WuXi AppTec
  • PyschoGenics
  • Evotec (Cyprotex)
  • QPS
  • Aurigene Pharmaceutical Services
  • Frontage Laboratories
  • Dalriada
  • Sygnature Discovery
  • Admescope
  • Imavita
  • IQVIA Laboratories
  • Pharmaron

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Preclinical Pharmacokinetics Services Market by Type
  3. 1.2.1 Global Preclinical Pharmacokinetics Services Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 LC-MS/MS-Based Preclinical Pharmacokinetics Service
  5. 1.2.3 Immunoassay-Based Preclinical Pharmacokinetics Service
  6. 1.2.4 Others
  7. 1.3 Preclinical Pharmacokinetics Services Market by Application
  8. 1.3.1 Global Preclinical Pharmacokinetics Services Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Innovative Small Molecule Drugs
  10. 1.3.3 Biopharmaceuticals
  11. 1.3.4 Traditional Chinese Medicine & Natural Products
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Preclinical Pharmacokinetics Services Market Dynamics
  1. 2.1 Preclinical Pharmacokinetics Services Industry Trends
  2. 2.2 Preclinical Pharmacokinetics Services Industry Drivers
  3. 2.3 Preclinical Pharmacokinetics Services Industry Opportunities and Challenges
  4. 2.4 Preclinical Pharmacokinetics Services Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Preclinical Pharmacokinetics Services Market Perspective (2021-2032)
  2. 3.2 Global Preclinical Pharmacokinetics Services Growth Trends by Region
  3. 3.2.1 Global Preclinical Pharmacokinetics Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Preclinical Pharmacokinetics Services Market Size by Region (2021-2026)
  5. 3.2.3 Global Preclinical Pharmacokinetics Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Preclinical Pharmacokinetics Services Revenue by Players
  2. 4.1.1 Global Preclinical Pharmacokinetics Services Revenue by Players (2021-2026)
  3. 4.1.2 Global Preclinical Pharmacokinetics Services Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Preclinical Pharmacokinetics Services Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Preclinical Pharmacokinetics Services Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Preclinical Pharmacokinetics Services Key Players Headquarters & Area Served
  7. 4.4 Global Preclinical Pharmacokinetics Services Players, Product Type & Application
  8. 4.5 Global Preclinical Pharmacokinetics Services Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Preclinical Pharmacokinetics Services Market CR5 and HHI
  11. 4.6.3 2025 Preclinical Pharmacokinetics Services Tier 1, Tier 2, and Tier 3
5 Preclinical Pharmacokinetics Services Market Size by Type
  1. 5.1 Global Preclinical Pharmacokinetics Services Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 5.3 Global Preclinical Pharmacokinetics Services Revenue Market Share by Type (2021-2032)
6 Preclinical Pharmacokinetics Services Market Size by Application
  1. 6.1 Global Preclinical Pharmacokinetics Services Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  3. 6.3 Global Preclinical Pharmacokinetics Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Porsolt
  2. 7.1.1 Porsolt Company Information
  3. 7.1.2 Porsolt Business Overview
  4. 7.1.3 Porsolt Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Porsolt Preclinical Pharmacokinetics Services Product Portfolio
  6. 7.1.5 Porsolt Recent Developments
  7. 7.2 Altasciences
  8. 7.2.1 Altasciences Company Information
  9. 7.2.2 Altasciences Business Overview
  10. 7.2.3 Altasciences Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Altasciences Preclinical Pharmacokinetics Services Product Portfolio
  12. 7.2.5 Altasciences Recent Developments
  13. 7.3 Biocytogen
  14. 7.3.1 Biocytogen Company Information
  15. 7.3.2 Biocytogen Business Overview
  16. 7.3.3 Biocytogen Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biocytogen Preclinical Pharmacokinetics Services Product Portfolio
  18. 7.3.5 Biocytogen Recent Developments
  19. 7.4 Charles River Laboratories
  20. 7.4.1 Charles River Laboratories Company Information
  21. 7.4.2 Charles River Laboratories Business Overview
  22. 7.4.3 Charles River Laboratories Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Charles River Laboratories Preclinical Pharmacokinetics Services Product Portfolio
  24. 7.4.5 Charles River Laboratories Recent Developments
  25. 7.5 WuXi AppTec
  26. 7.5.1 WuXi AppTec Company Information
  27. 7.5.2 WuXi AppTec Business Overview
  28. 7.5.3 WuXi AppTec Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  29. 7.5.4 WuXi AppTec Preclinical Pharmacokinetics Services Product Portfolio
  30. 7.5.5 WuXi AppTec Recent Developments
  31. 7.6 PyschoGenics
  32. 7.6.1 PyschoGenics Company Information
  33. 7.6.2 PyschoGenics Business Overview
  34. 7.6.3 PyschoGenics Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  35. 7.6.4 PyschoGenics Preclinical Pharmacokinetics Services Product Portfolio
  36. 7.6.5 PyschoGenics Recent Developments
  37. 7.7 Evotec (Cyprotex)
  38. 7.7.1 Evotec (Cyprotex) Company Information
  39. 7.7.2 Evotec (Cyprotex) Business Overview
  40. 7.7.3 Evotec (Cyprotex) Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Evotec (Cyprotex) Preclinical Pharmacokinetics Services Product Portfolio
  42. 7.7.5 Evotec (Cyprotex) Recent Developments
  43. 7.8 QPS
  44. 7.8.1 QPS Company Information
  45. 7.8.2 QPS Business Overview
  46. 7.8.3 QPS Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  47. 7.8.4 QPS Preclinical Pharmacokinetics Services Product Portfolio
  48. 7.8.5 QPS Recent Developments
  49. 7.9 Aurigene Pharmaceutical Services
  50. 7.9.1 Aurigene Pharmaceutical Services Company Information
  51. 7.9.2 Aurigene Pharmaceutical Services Business Overview
  52. 7.9.3 Aurigene Pharmaceutical Services Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Aurigene Pharmaceutical Services Preclinical Pharmacokinetics Services Product Portfolio
  54. 7.9.5 Aurigene Pharmaceutical Services Recent Developments
  55. 7.10 Frontage Laboratories
  56. 7.10.1 Frontage Laboratories Company Information
  57. 7.10.2 Frontage Laboratories Business Overview
  58. 7.10.3 Frontage Laboratories Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Frontage Laboratories Preclinical Pharmacokinetics Services Product Portfolio
  60. 7.10.5 Frontage Laboratories Recent Developments
  61. 7.11 Dalriada
  62. 7.11.1 Dalriada Company Information
  63. 7.11.2 Dalriada Business Overview
  64. 7.11.3 Dalriada Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dalriada Preclinical Pharmacokinetics Services Product Portfolio
  66. 7.11.5 Dalriada Recent Developments
  67. 7.12 Sygnature Discovery
  68. 7.12.1 Sygnature Discovery Company Information
  69. 7.12.2 Sygnature Discovery Business Overview
  70. 7.12.3 Sygnature Discovery Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sygnature Discovery Preclinical Pharmacokinetics Services Product Portfolio
  72. 7.12.5 Sygnature Discovery Recent Developments
  73. 7.13 Admescope
  74. 7.13.1 Admescope Company Information
  75. 7.13.2 Admescope Business Overview
  76. 7.13.3 Admescope Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Admescope Preclinical Pharmacokinetics Services Product Portfolio
  78. 7.13.5 Admescope Recent Developments
  79. 7.14 Imavita
  80. 7.14.1 Imavita Company Information
  81. 7.14.2 Imavita Business Overview
  82. 7.14.3 Imavita Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Imavita Preclinical Pharmacokinetics Services Product Portfolio
  84. 7.14.5 Imavita Recent Developments
  85. 7.15 IQVIA Laboratories
  86. 7.15.1 IQVIA Laboratories Company Information
  87. 7.15.2 IQVIA Laboratories Business Overview
  88. 7.15.3 IQVIA Laboratories Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  89. 7.15.4 IQVIA Laboratories Preclinical Pharmacokinetics Services Product Portfolio
  90. 7.15.5 IQVIA Laboratories Recent Developments
  91. 7.16 Pharmaron
  92. 7.16.1 Pharmaron Company Information
  93. 7.16.2 Pharmaron Business Overview
  94. 7.16.3 Pharmaron Preclinical Pharmacokinetics Services Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Pharmaron Preclinical Pharmacokinetics Services Product Portfolio
  96. 7.16.5 Pharmaron Recent Developments
8 North America
  1. 8.1 North America Preclinical Pharmacokinetics Services Revenue (2021-2032)
  2. 8.2 North America Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 8.2.1 North America Preclinical Pharmacokinetics Services Revenue by Type (2021-2026)
  4. 8.2.2 North America Preclinical Pharmacokinetics Services Revenue by Type (2027-2032)
  5. 8.3 North America Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032)
  6. 8.4 North America Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  7. 8.4.1 North America Preclinical Pharmacokinetics Services Revenue by Application (2021-2026)
  8. 8.4.2 North America Preclinical Pharmacokinetics Services Revenue by Application (2027-2032)
  9. 8.5 North America Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032)
  10. 8.6 North America Preclinical Pharmacokinetics Services Revenue by Country
  11. 8.6.1 North America Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Preclinical Pharmacokinetics Services Revenue by Country (2021-2026)
  13. 8.6.3 North America Preclinical Pharmacokinetics Services Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Preclinical Pharmacokinetics Services Revenue (2021-2032)
  2. 9.2 Europe Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 9.2.1 Europe Preclinical Pharmacokinetics Services Revenue by Type (2021-2026)
  4. 9.2.2 Europe Preclinical Pharmacokinetics Services Revenue by Type (2027-2032)
  5. 9.3 Europe Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032)
  6. 9.4 Europe Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  7. 9.4.1 Europe Preclinical Pharmacokinetics Services Revenue by Application (2021-2026)
  8. 9.4.2 Europe Preclinical Pharmacokinetics Services Revenue by Application (2027-2032)
  9. 9.5 Europe Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032)
  10. 9.6 Europe Preclinical Pharmacokinetics Services Revenue by Country
  11. 9.6.1 Europe Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Preclinical Pharmacokinetics Services Revenue by Country (2021-2026)
  13. 9.6.3 Europe Preclinical Pharmacokinetics Services Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Preclinical Pharmacokinetics Services Revenue (2021-2032)
  2. 10.2 China Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 10.2.1 China Preclinical Pharmacokinetics Services Revenue by Type (2021-2026)
  4. 10.2.2 China Preclinical Pharmacokinetics Services Revenue by Type (2027-2032)
  5. 10.3 China Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032)
  6. 10.4 China Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  7. 10.4.1 China Preclinical Pharmacokinetics Services Revenue by Application (2021-2026)
  8. 10.4.2 China Preclinical Pharmacokinetics Services Revenue by Application (2027-2032)
  9. 10.5 China Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Preclinical Pharmacokinetics Services Revenue (2021-2032)
  2. 11.2 Asia Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 11.2.1 Asia Preclinical Pharmacokinetics Services Revenue by Type (2021-2026)
  4. 11.2.2 Asia Preclinical Pharmacokinetics Services Revenue by Type (2027-2032)
  5. 11.3 Asia Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032)
  6. 11.4 Asia Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  7. 11.4.1 Asia Preclinical Pharmacokinetics Services Revenue by Application (2021-2026)
  8. 11.4.2 Asia Preclinical Pharmacokinetics Services Revenue by Application (2027-2032)
  9. 11.5 Asia Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032)
  10. 11.6 Asia Preclinical Pharmacokinetics Services Revenue by Country
  11. 11.6.1 Asia Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Preclinical Pharmacokinetics Services Revenue by Country (2021-2026)
  13. 11.6.3 Asia Preclinical Pharmacokinetics Services Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Preclinical Pharmacokinetics Services Revenue (2021-2032)
  2. 12.2 SAMEA Preclinical Pharmacokinetics Services Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Preclinical Pharmacokinetics Services Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Preclinical Pharmacokinetics Services Revenue by Type (2027-2032)
  5. 12.3 SAMEA Preclinical Pharmacokinetics Services Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Preclinical Pharmacokinetics Services Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Preclinical Pharmacokinetics Services Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Preclinical Pharmacokinetics Services Revenue by Application (2027-2032)
  9. 12.5 SAMEA Preclinical Pharmacokinetics Services Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Preclinical Pharmacokinetics Services Revenue by Country
  11. 12.6.1 SAMEA Preclinical Pharmacokinetics Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Preclinical Pharmacokinetics Services Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Preclinical Pharmacokinetics Services Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst